Statins and dementia · Cognitive baseline

Statins and Dementia: Measuring Cognition in Patients on Statins

In patients on statins, trials find no cognitive harm on average, but a small, reversible effect in a susceptible few can only be tested in the individual. A documented cognitive baseline makes that question answerable by measurement rather than recall.

Population data and the individual patient answer different questions. Only one of them can be settled in the exam room, and only with a baseline recorded first.

On statins and dementia, the population answer is settled enough to state plainly: randomized trials find no cognitive harm on average, and observational cohorts find less dementia among users. What remains is smaller and harder. Chapter 4 of The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and its video, frame it as an individual question: in a given patient with new cognitive complaints on a statin, is the drug involved? Measura [Cardiometabolic and Autonomic Health Analysis] does not answer that for the clinician. It makes the question answerable by measurement rather than recall.

How do statins affect cholesterol in the brain?

The central nervous system is about 2.1% of body weight and holds about 23% of the body’s sterol pool, essentially all of it synthesized locally behind the blood–brain barrier. Lipoprotein cholesterol does not supply it, which is why a serum lipid panel is nearly silent on brain cholesterol status. Myelin is lipid-dense, and when mice lacked cholesterol synthesis in oligodendrocytes, myelination slowed and thinned without stopping. Glia supply the cholesterol that synapse formation depends on.

HMG-CoA reductase is not a hepatic monopoly. Lipophilic agents cross the barrier more readily, and the brain’s exit marker, 24S-hydroxycholesterol, fell 45% at six weeks and 53% at 24 weeks on simvastatin 80 mg in 18 hypercholesterolemic patients. In Alzheimer’s patients the marker also fell on regimens that included pravastatin, though part of that fall tracks LDL clearance rather than brain synthesis. Hydrophilic does not mean invisible to the brain pool.

Do statins cause dementia? What the outcome data show, and what they could not see

Solubility has not predicted harm. ASPREE, with 18,846 participants aged 65 and over, found no association between statin use and dementia, MCI or cognitive change, and no difference by solubility; 36 observational studies agreed on the solubility point. On the randomized side, 25 placebo-controlled trials in 46,836 people showed no cognitive effect, and the 2026 individual-participant analysis of 19 blinded trials and 123,940 people concluded the data do not support a causal link to cognitive impairment.

The design limits are what matter clinically. Cognition was not a primary or secondary outcome in the large cardiovascular trials. Adverse-event capture was spontaneous reporting rather than testing. ASPREE excluded dementia, the population the withdrawal signal came from, and the cohorts carry reverse causation because patients developing dementia stop their statins. Neither design could detect a small, reversible effect confined to a susceptible minority, and that is what the 2012 class labeling describes: rare, generally nonserious, reversible, with onset from a day to years and resolution at a median of three weeks.

There is an admission worth making here. The mechanism is strong enough that one would expect a population signal, and the populations have declined to produce one. Dr. Padda says so directly rather than bending the data, and the honest consequence is a narrower claim: one that can be tested in a single patient.

Padala, read at its actual size

The withdrawal and rechallenge pilot enrolled 18 older veterans with Alzheimer’s dementia. MMSE rose 1.9 points during six weeks off the statin (P = 0.014) and fell 1.9 points on rechallenge (P = 0.007); the CERAD battery did not change (P = 0.31). It was open-label and single-arm, with no control, and the change was smaller than its own standard deviation. Cochrane’s pooling of four double-blind trials in 1,154 Alzheimer’s patients found MMSE 0.32 points lower on statin, not significant. The one blinded withdrawal phase ever run, inside LEADe, was never reported.

What Padala contributes is design, not proof: onset after exposure, resolution off it, recurrence on it, measured with the same instrument each time. That is ordinary adverse drug reaction logic, and it works only if the first measurement exists before the question is asked.

How should cognition be measured in patients on statins?

All of this points to one workflow change: document cognition before it becomes a complaint.

1. Baseline at initiation or the next wellness visit. A structured cognitive assessment for older patients on or starting a lipophilic statin, and for any patient with existing cognitive impairment, recorded as a comparable score rather than a narrative. The annual wellness visit is the natural home for it.
2. Repeat with the same instrument when a complaint appears. Comparison with the patient’s own baseline separates a change from a lifelong pattern, and avoids reading an MMSE against a battery that behaves differently.
3. If the treating physician elects a supervised off-and-on trial, the same assessment at each phase gives it a readable outcome. The label’s median three-week resolution and Padala’s six-week phases frame the timing. Whether to interrupt therapy, and in whom, stays with the treating physician and the patient; after a myocardial infarction the calculus is different.
4. Measure the metabolic side as well. In the 2024 CTT analysis of 23 blinded trials, high-intensity therapy carried new-onset diabetes at 4.8% a year against 3.5%, and about 62% of new cases arose in the top quarter of baseline glycemia. Laboratory panels characterizing insulin resistance identify that quarter explicitly.

For older patients, the same visit can pair the cognitive baseline with vestibular and balance testing, so cognitive and fall-risk findings enter one plan, as outlined in cognitive assessment and fall prevention. Arterial stiffness and endothelial function keeps the vascular indication, the reason the statin was started, documented on its own terms.

The barrier is structural: a short visit, a medication list reconciled from memory, and a cognitive complaint that defaults to age. A documented baseline makes the complaint auditable. Written into a standing order, the protocol does not depend on which clinician is in the room, and cognitive plus cardiometabolic findings in one encounter serve MIPS and quality reporting.

The wider point for practice

The brain builds and maintains itself from lipids for decades, and for fifty years dietary guidance steered patients away from the foods densest in them. That is context, not a prescription. The instrument that matters in the exam room is the one that makes an individual effect visible. The grading of each claim, including the trial record against the hypothesis, is in the Chapter 4 book companion, and the metabolic precursor is covered in insulin resistance and dementia screening.

Frequently asked questions

Do statins increase dementia risk?

Not on current evidence. Randomized trials covering well over a hundred thousand participants show no cognitive harm, and observational meta-analysis gives an odds ratio of 0.80 for dementia among users, likely inflated by healthy-adherer bias and reverse causation. The open question is an individual, reversible effect in a susceptible minority, not population risk. The framing is expanded in clinical rationale.

Which cognitive instrument should anchor a withdrawal and rechallenge trial?

The one used at baseline. In Padala’s pilot the MMSE moved while the longer CERAD battery did not, which shows instruments can disagree. Consistency of instrument, conditions and timing matters more than which validated tool is chosen, because the patient is compared only with themselves. Reading serial results is covered in interpreting the report.

Does lipophilicity alone justify a management change?

Outcome studies have not shown a dementia difference between lipophilic and hydrophilic agents, and the brain cholesterol exit marker has fallen on regimens that included pravastatin. Solubility alone is weak grounds for a decision. A documented change on a repeated cognitive measure, in a patient with a plausible timeline, is a stronger one. Patient selection is outlined in selection criteria.

How should serial cognitive results be documented?

As scored results in structured fields, dated and tied to the instrument, rather than as narrative impressions. That lets a later complaint be compared directly with baseline, supports quality documentation, and keeps the medication timeline beside the scores. The EMR workflow is described in getting results into the record.

Is there a version written for patients?

Yes. The patient article explains why the brain makes its own cholesterol, why a lipid panel cannot see it, what the statin memory evidence shows, and why nobody should stop a statin on their own. It prepares patients for a measured conversation. It is available as statins and memory loss for patients.

Will memory improve after stopping a statin?

In the rare cases described by the 2012 class labeling, symptoms resolved at a median of three weeks off the drug. In Padala’s pilot of 18 veterans with Alzheimer’s dementia, MMSE rose 1.9 points during six weeks off the statin and fell 1.9 points on rechallenge, with no control group. Whether to interrupt therapy, and in whom, stays with the treating physician and the patient.

Do statins raise the risk of new diabetes?

In the 2024 CTT analysis of 23 blinded trials, high-intensity therapy carried new-onset diabetes at 4.8% a year against 3.5%, and about 62% of new cases arose in the top quarter of baseline glycemia. Laboratory panels that characterize insulin resistance identify that quarter explicitly, which is why the metabolic side belongs in the same protocol as the cognitive baseline.

Does a lipid panel show brain cholesterol?

No. The central nervous system is about 2.1% of body weight and holds about 23% of the body’s sterol pool, essentially all of it synthesized locally behind the blood–brain barrier. Lipoprotein cholesterol does not supply it, so a serum lipid panel is nearly silent on brain cholesterol status. The measurement that can show an individual effect is a repeated cognitive assessment.

References

• Dietschy, J. M., & Turley, S. D. (2004). Thematic review series: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. Journal of Lipid Research, 45(8), 1375–1397. https://doi.org/10.1194/jlr.R400004-JLR200
• Saher, G., Brügger, B., Lappe-Siefke, C., Möbius, W., Tozawa, R., Wehr, M. C., Wieland, F., Ishibashi, S., & Nave, K.-A. (2005). High cholesterol level is essential for myelin membrane growth. Nature Neuroscience, 8(4), 468–475. https://doi.org/10.1038/nn1426
• Locatelli, S., Lütjohann, D., Schmidt, H. H. J., Otto, C., Beisiegel, U., & von Bergmann, K. (2002). Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: Evidence that simvastatin affects cholesterol metabolism in the human brain. Archives of Neurology, 59(2), 213–216. https://doi.org/10.1001/archneur.59.2.213
• Zhou, Z., Ryan, J., Ernst, M. E., Zoungas, S., Tonkin, A. M., Woods, R. L., McNeil, J. J., Reid, C. M., Curtis, A. J., Wolfe, R., Wrigglesworth, J., Shah, R. C., Storey, E., Murray, A., Orchard, S. G., Nelson, M. R., & ASPREE Investigator Group. (2021). Effect of statin therapy on cognitive decline and incident dementia in older adults. Journal of the American College of Cardiology, 77(25), 3145–3156. https://doi.org/10.1016/j.jacc.2021.04.075
• Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022). Statin use and risk of dementia or Alzheimer’s disease: A systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology, 29(5), 804–814. https://doi.org/10.1093/eurjpc/zwab208
• Ott, B. R., Daiello, L. A., Dahabreh, I. J., Springate, B. A., Bixby, K., Murali, M., & Trikalinos, T. A. (2015). Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. Journal of General Internal Medicine, 30(3), 348–358. https://doi.org/10.1007/s11606-014-3115-3
• Cholesterol Treatment Trialists’ Collaboration. (2026). Assessment of adverse effects attributed to statin therapy in product labels: A meta-analysis of double-blind randomised controlled trials. The Lancet, 407(10529), 689–703. https://doi.org/10.1016/S0140-6736(25)01578-8
• Padala, K. P., Padala, P. R., McNeilly, D. P., Geske, J. A., Sullivan, D. H., & Potter, J. F. (2012). The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: A prospective withdrawal and rechallenge pilot study. The American Journal of Geriatric Pharmacotherapy, 10(5), 296–302. https://doi.org/10.1016/j.amjopharm.2012.08.002
• McGuinness, B., Craig, D., Bullock, R., Malouf, R., & Passmore, P. (2014). Statins for the treatment of dementia. Cochrane Database of Systematic Reviews, 2014(7), Article CD007514. https://doi.org/10.1002/14651858.CD007514.pub3
• Cholesterol Treatment Trialists’ (CTT) Collaboration. (2024). Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: An individual participant data meta-analysis. The Lancet Diabetes & Endocrinology, 12(5), 306–319. https://doi.org/10.1016/S2213-8587(24)00040-8

Related reading

• Insulin Resistance and Dementia: Screening Past the Glucose
• Metformin B12 Deficiency: Screening Beyond the Serum Level
• Cognitive Assessment

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.